Glufosfamide (Baxter Oncology) |
| |
| Authors: | Niculescu-Duvaz Ion |
| |
| Affiliation: | CRC Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey, UK. ion@icr.ac.uk |
| |
| Abstract: | Glufosfamide is a sugar phosphamide alkylating agent under development by Baxter Oncology (formerly ASTA Medica) as a potential treatment for cancer. By April 2000, glufosfamide had commenced phase II trials, one of which involved intrathecal administration to patients with carcinomatous meningioma. |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
|
